In a report released on January 14, Evan Seigerman from BMO Capital reiterated a Hold rating on Replimune Group, with a price target of $11.00. The company’s shares closed yesterday at $7.71.

Python -O won’t magically make every script faster, but in the right workloads it’s a free win—here’s how to test it safely.

Why write ten lines of code when one will do? From magic variable swaps to high-speed data counting, these Python snippets ...

Audience members cheer familiar bits from ‘Monty Python and the Holy Grail’ and the troupe’s TV show in this rollicking touring musical.

Burmese pythons are an invasive species in South Florida, originally from Southeast Asia and introduced through the pet trade. The non-venomous constrictors disrupt the ecosystem by preying on native ...

TIOBE Index for February 2026: Top 10 Most Popular Programming Languages Your email has been sent February’s TIOBE Index shows a leaderboard that looks steady at first glance, but small shifts beneath ...

Get the scoop on the most recent ranking from the Tiobe programming language index, learn a no-fuss way to distribute DIY tooling across Python projects, and take a peek at ComfyUI: interactive, ...

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip ...